GO
Loading...

Biotechnology

More

  • JERUSALEM, March 25- Israeli biopharmaceutical company BioLineRX Ltd said on Wednesday an early stage trial for a drug that uses stem cells to treat leukaemia and other blood cancers met all safety and efficacy goals. Current stem cell treatments require four or five days of injections of material from a donor to get into the bloodstream, but BioLineRX said its...

  • TEL AVIV/ FRANKFURT, March 12- Two years after scientists cooked up the first test tube beef hamburger, researchers in Israel are working on an even trickier recipe: the world's first lab-grown chicken. Professor Amit Gefen, a bioengineer at Tel Aviv University, has begun a year-long feasibility study into manufacturing chicken in a lab, funded by a non-profit...

  • Biotech brawl: Bull vs. ...bull   Friday, 27 Feb 2015 | 3:16 PM ET
    Biotech brawl: Bull vs. ...bull

    Eric Schmidt, Cowen & Co. biotech analyst, thinks biotech will continue to be a great business and will move higher. Insight, with Geoff Porges, Sanford Bernstein.

  • Feb 20- Europe has approved the Western world's first medicine containing stem cells to treat a rare condition caused by burns to the eye, marking a milestone in the use of the technology. Holoclar, from privately held Italian company Chiesi, was given a marketing green light on Friday by the European Commission for treating so-called limbal stem cell...

  • Who can beat the 'superbug'?   Thursday, 19 Feb 2015 | 5:27 PM ET
    Who can beat the 'superbug'?

    A new antibiotic-resistant "superbug" may have contributed to the deaths of 2 patients at Ronald Reagan-UCLA Medical Center. What companies may be on track to combat the deadly virus, with CNBC's Meg Tirrell.

  • It turns out Genghis Khan made a whole lot of us Friday, 30 Jan 2015 | 3:00 PM ET
    Statue of Genghis Khan

    New DNA evidence says significant chunks of humanity may carry genes from a few powerful men, including Genghis Khan.

  • US earnings: 'Tech to the rescue'   Thursday, 29 Jan 2015 | 5:00 AM ET
    US earnings: 'Tech to the rescue'

    Caterpillar and 3Ms' poor earnings performance "spooked investors", however tech and healthcare are expected to save the earnings season, says Christine Short, senior vice president at Estimize.

  • The rise and rise of biotech stocks?   Friday, 16 Jan 2015 | 5:20 AM ET
    The rise and rise of biotech stocks?

    Biotech stocks in the U.S. have outperformed significantly over the last three years -- and this can continue, says Matthew Roden, executive director of biotechnology equity research at UBS AG.

  • Biopharma's challenges in 2015   Wednesday, 14 Jan 2015 | 9:30 AM ET
    Biopharma's challenges in 2015

    Biopharma executives at the J.P. Morgan Healthcare Conference talk about this year's biggest challenges.

  • I am a better person: Sam Waksal   Tuesday, 13 Jan 2015 | 8:36 AM ET
    I am a better person: Sam Waksal

    Sam Waksal, former Imclone Systems CEO, reveals how the ImClone scandal has impacted his life.

  • I'm not running the show: Sam Waksal   Tuesday, 13 Jan 2015 | 8:33 AM ET
    I'm not running the show: Sam Waksal

    CNBC's Meg Tirrell, and Sam Waksal, Kadmon founder & chairman, discusses his role in the company.

  • Sam Waksal's IPO biotech plans   Tuesday, 13 Jan 2015 | 8:31 AM ET
    Sam Waksal's IPO biotech plans

    CNBC's Meg Tirrell, and Sam Waksal, Kadmon founder & chairman, discuss plans to take the biotech company public.

  • Biogen Idec beefs up pain pipeline   Monday, 12 Jan 2015 | 3:16 PM ET
    Biogen Idec beefs up pain pipeline

    Dr. George Scangos, Biogen Idec CEO, discusses new therapies in multiple sclerosis, Alzheimer's disease and pain.

  • 23andMe partners with big pharma   Monday, 12 Jan 2015 | 12:20 PM ET
    23andMe partners with big pharma

    Anne Wojcicki, co-founder and CEO of genetic-testing startup 23andMe, discusses the new deals with Pfizer and Genentech.

  • Celgene CEO: Creating a great future   Monday, 12 Jan 2015 | 11:45 AM ET
    Celgene CEO: Creating a great future

    CNBC's Meg Tirrell speaks to Robert Hugin, Celgene chairman & CEO, about the company's ambitious long-term guidance and broad-based drug pipeline.

  • Analyzing Eli Lilly's drug pipeline   Monday, 12 Jan 2015 | 10:15 AM ET
    Analyzing Eli Lilly's drug pipeline

    CNBC's Meg Tirrell speaks to John Lechleiter, Eli Lilly CEO, about the strength and outlook for the health care sector, and what new drugs he's most excited about.

  • Stock moving information kept behind doors   Thursday, 8 Jan 2015 | 2:37 PM ET
    Stock moving information kept behind doors

    CNBC's Meg Tirrell provides insight to the debate over transparency from biotech companies. Biotech investor Brad Loncar, thinks this is just an awareness issue.

  • Jim Cramer's top 10 biotech players   Tuesday, 6 Jan 2015 | 6:15 PM ET
    Cramer: This sector was up 33% last year

    The biotechs were one of the best performing sectors for 2014. Can it work wonders for 2015? Cramer gives his top players in the biotech space.

  • Biotech's strong pipeline   Tuesday, 6 Jan 2015 | 5:45 PM ET
    Biotech's strong pipeline

    A total of 71 biotech companies went public in 2014. Cowen Group President and Cowen & Company CEO Jeffrey Solomon, discusses the market sentiment toward the sector.

  • Will biotech bull run continue?   Tuesday, 6 Jan 2015 | 10:43 AM ET
    Will biotech bull run continue?

    Discussing the outlook on the pharmaceutical sector, including leaders like Gilead and Celgene, with Michael Yee, RBC Capital Markets biotech analyst.